thres
$BCLI Even AI will tell you which ALS-Specific Drug (approved or not) has proven to be more popular with ALS patients.
Most Campaigned-For Experimental Therapy: NurOwn Among unapproved clinical-stage treatments, NurOwn (an autologous stem-cell therapy developed by BCLI) has generated the most intense patient loyalty and grassroots mobilization. • Why Patients Rally Behind It. Many clinical trial participants and their families have shared dramatic personal testimonials claiming NurOwn stabilized their progression or restored lost function. Despite failing its initial Phase III primary endpoints and receiving a 17–1 vote against approval from an FDA advisory panel in 2023, thousands of patients petitioned regulators to keep it accessible. • Current Status. Following strong long-term survival data from its Expanded Access Program—where Brain Storm Cell Therapeutics reported that 9 out of 10 participants survived past five years—the therapy advanced toward a registrational Phase 3b trial.
9
:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_nasdaq_original_jpg_ad4cc4a377.webp)
:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Flarge_als_jpg_4f217a4ab6.webp)
:format(webp)/https%3A%2F%2Fst-everywhere-cms-prod.s3.us-east-1.amazonaws.com%2Fwealthyvc_12445ce5f9.png)